Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 12/20 | 0.48 |
| ▸ | GSK3A | P49840 | 11/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659375 | 1.00 | AHR (0.48) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL30493623 | 0.82 | NPC1 (0.50) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL2233893 | 0.82 | NPC1 (0.50) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL3053419 | 0.79 | MAPT (0.53) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL5826323 | 0.78 | GSK3A (0.57) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL8484211 | 0.78 | CYP1A2 (0.56) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL10558162 | 0.78 | BRD4 (0.40) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL299769 | 0.77 | TDP2 (0.52) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL14852833 | 0.75 | GLO1 (0.43) | AHRPDK2GSK3BGSK3ACDK5 | |
| SCHEMBL673377 | 0.74 | CYP11B1 (0.42) | GSK3BGSK3ACDK5CDK5R1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | claimed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | claimed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | claimed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735420-A1 | ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727548-A1 | METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4573080-A1 | INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS | Cytokinetics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025090640-A1 | SOLID FORMULATIONS AND POLYMORPHIC FORMS OF INDOLINE INHIBITORS OF KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-111278822-B | Crystalline forms | 阿雷生物药品公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022116995-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-110357878-B | 1, 3-dihydro-2H-pyrrolo [3,2-b ] pyridin-2-one derivatives and medical use thereof | 武汉誉祥医药科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110357878-B | 1, 3-dihydro-2H-pyrrolo [3,2-b ] pyridin-2-one derivatives and medical use thereof | 武汉誉祥医药科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11299510-B2 | Substituted pyridopyrrolopyrimidine ribonucleosides for therapeutic uses | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | AHR 678/4885PDK2 1096/4885GSK3B 2018/4885 |
| US-11299510-B2 | Substituted pyridopyrrolopyrimidine ribonucleosides for therapeutic uses | TYMP, DPYD, RRM2 | AHR 3225/4885PDK2 445/4885GSK3B 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.